Compare Aurora Cannabis Inc (ACB) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

HLAL trades at $71.16, up 1.22% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $71-$73, with support at $70 and $69. Recent dividend activity includes a $0.02 distribution scheduled for June 2026, though key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity.

The outlook remains cautious due to weak technical momentum and lack of recent financial data. Risks include market volatility and potential earnings uncertainty, while opportunities hinge on future corporate updates. Investors should await fresh earnings reports for a clearer valuation picture amid current bearish signals.